Qnostics develops SARS-CoV-2 test controls

Qnostics, a world leading manufacturer of QC solutions for molecular infectious disease testing, has developed a range of products designed to support the validation, verification and performance monitoring of molecular assays used in the testing of SARS-CoV-2.
Conveniently combining SARS-CoV-2, Flu A, Flu B and RSV, the new RTX plus control is ideal for use with multiplex assays. A dedicated SARS-CoV-2 control is also available.
Comprising the full SARS CoV-2 genome, the control range is compatible for use with the majority of commercial and in-house assays. Whole pathogen controls are ideal for full-process validation, monitoring the testing process from extraction to amplification and detection, ensuring the ultimate quality assurance in laboratories.
Additionally, the third-party nature of these controls ensures an independent, unbiased assessment of assay performance in-line with ISO 15189 regulatory requirements. Supplied in a liquid easy to use format, minimal preparation is required. A complementary negative control is also available delivering a complete testing package.
For more information, visit: https://www.randox.com/sars-cov-2-molecular-control/
Supplier: [No title]
Website: https://www.randox.com/sars-cov-2-molecular-control/

Mail the supplier